Table I.
Summary of patient's general information and management involved in this study. Total number of patients: 53.
| Clinical parameters | Number of cases (n) | (%) |
|---|---|---|
| Age, years | ||
| <58 | 26 | 49.0 |
| ≥58 | 27 | 51.0 |
| Sex | ||
| Male | 40 | 75.5 |
| Female | 13 | 24.5 |
| Tumor size, cm | ||
| <5 | 34 | 64.2 |
| ≥5 | 19 | 35.8 |
| Tumor location | ||
| Cardia, fundus, body | 28 | 52.8 |
| Antral | 25 | 47.2 |
| TNM stage | ||
| I–II | 26 | 49.0 |
| III–IV | 27 | 51.0 |
| Tumor depth | ||
| T1-T2 | 11 | 20.8 |
| T3-T4 | 42 | 79.2 |
| Lymph node metastasis | ||
| Yes | 36 | 68.0 |
| No | 17 | 32.0 |
| Histological differentiation | ||
| Differentiated | 24 | 45.3 |
| Undifferentiated | 29 | 54.7 |
| Chemotherapy regimen | ||
| FOLFOX | 22 | 41.5 |
| EOX | 16 | 30.2 |
| Others (SOX, ECX, EOX, S1) | 13 | 24.5 |
| Chemoradiotherapy | 2 | 3.8 |
| Chemotherapy cycle | ||
| 2 | 8 | 15.1 |
| 3 | 17 | 32.1 |
| ≥4 | 28 | 52.8 |
| Tumor regression grade | ||
| 0–2 | 33 | 62.3 |
| 3–4 | 20 | 37.7 |
| Surgical types | ||
| Complete resection | 25 | 47.2 |
| Distal resection | 25 | 47.2 |
| Proximal resection | 1 | 1.9 |
| Partial resection | 2 | 3.7 |
ECX, epirubicin + cisplatin + capecitabine; EOS, epirubicin + oxaplatin + tegafur; EOX, epirubicin + oxaplatin + capecitabine; FOLFOX, oxaplatin + leucovorin + 5-FU; S1, tegafur; SOX, oxaplatin + tegafur.